(Q37679899)

21 August 2017

1 reference

title

Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers (English)

1 reference

21 August 2017

1

Christian Höcht

1 reference

21 August 2017

author name string

Facundo Martín Bertera

series ordinal

2

1 reference

21 August 2017

Marcos Alejandro Mayer

series ordinal

3

1 reference

21 August 2017

Carlos Alberto Taira

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

199-211

1 reference

Overcoming barriers to effective blood pressure control in patients with hypertension

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

What factors contribute to the inadequate control of elevated blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Variability in response to cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Antihypertensive therapy: special focus on drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinical pharmacokinetics of vasodilators. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinical pharmacokinetics and pharmacodynamics of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Stereoselective pharmacokinetics of dihydropyridine calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Stereoselectivity in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The vasodilatory beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Monitoring of verapamil enantiomers concentration in overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinical pharmacokinetics of candesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Olmesartan medoxomil: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Nebivolol: a review of its use in the management of hypertension and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Liver function and phase I drug metabolism in the elderly: a paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The effects of age and gender on the pharmacokinetics of irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinical pharmacokinetics of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Irbesartan: a review of its use in hypertension and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The pharmacokinetic profile of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinical implications of CYP3A polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Medication adherence and persistence as the cornerstone of effective antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

Pharmacology of valsartan, an angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903397381

10.1517/17425250903397381

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference